Skip to main content

Stem cell transplants curb disease activity in active MS

By MS Buddy ·

Summarized from Multiple sclerosis (Houndmills, Basingstoke, England), Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.

Review · selected people with active relapsing MS and other brain and nerve diseases

Research by Saira Afzal, Jeffrey Cohen and 1 colleague at Neurological Institute in the United States.

Can stem cell transplants control active relapsing MS?

Key Takeaway

Stem cell transplants can provide lasting control of disease activity in selected people with active relapsing MS.

Paper nerve branches sit within a curved protective layer, with most small paper shapes outside and a few nearby.
Credibility
Interest
Share:1 min read

What They Found

The review describes stem cell transplants (treatment using a person's own blood-forming stem cells) as highly effective for selected people with active relapsing MS. Studies and trials found lasting suppression of disease activity linked to inflammation (the body's immune response). Major medical organizations support this option for active MS that has not responded to highly effective MS medicines. The best preparation treatment before a transplant remains unclear. Researchers also remain unsure whether selecting particular stem cells improves results.

Who Should Care and Why

This review focuses mainly on selected people with active relapsing MS. It also discusses transplants for other diseases involving inflammation (the body's immune response) in the brain and nerves. Evidence for those other conditions comes mostly from reports describing small groups of patients. For MS, the review addresses where transplants fit among current treatment choices. It also highlights uncertainty about which people are most likely to benefit.

Important Considerations

This article reviews existing evidence rather than reporting a new trial, and the abstract gives no participant total. You cannot tell from this abstract which preparation treatment or patient selection approach is best. Ongoing trials that randomly assign treatments are expected to strengthen the evidence.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Multiple sclerosis (Houndmills, Basingstoke, England) by . Reproduced from the PubMed record.

Autologous hematopoietic stem cell transplantation has emerged as a highly effective treatment strategy for selected patients with active relapsing multiple sclerosis and is now being investigated in other neuroinflammatory diseases, including neuromyelitis optica spectrum disorder and stiff person syndrome, among others. Accumulating evidence from observational studies and clinical trials demonstrated sustained suppression of inflammatory disease activity in multiple sclerosis, whereas evidence in other neuroinflammatory diseases remains largely limited to case series. Major professional bodies have endorsed autologous hematopoietic stem cell transplantation as an option for active multiple sclerosis refractory to high-efficacy disease-modifying therapies. Nevertheless, even within the multiple sclerosis field, critical questions remain unresolved. The optimal conditioning regimen and benefit of CD34+ cell selection have not been established. Patient selection criteria require further refinement. Where to place autologous hematopoietic stem cell transplantation among current treatment options remains uncertain. Ongoing randomized trials are expected to substantially advance the evidence base.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Rounded stem cells with visible nuclei float against a muted blue-gray background.
MS stem cell transplants mostly done without admission

11/19/2026

A review of one MS stem cell transplant program found most procedures avoided hospital admission. Be

Read More
Paper bands support a bowl of blue droplets; a few drops sit outside, and a dotted path leads to a guiding hand.
Remotely guided muscle training eased urine leaks in MS

11/20/2026

A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac

Read More
Two curving ribbons, one with fewer loose knots; the knots on both ribbons are the same size and length.
MS drugs cut relapses but did not change relapse recovery

11/19/2026

Across four trials in relapsing-remitting MS, long-term treatments reduced relapses but did not chan

Read More
Brain outline filled with fine, branching nerve fibers on an off-white background.
In relapsing MS, Mavenclad users' thinking scores rose

11/14/2026

In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.

Read More
Two paper paths meet at an open junction, surrounded by layered shapes in muted colors.
When older adults with MS should stop drugs remains unclear

11/15/2026

A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older

Read More
Muted blue paths widen and join across soft gray layers on an off-white background.
MS treatment in Poland started sooner, reached more people

11/13/2026

From 2013 to 2024, more people with MS in Poland received treatment and started sooner. Stronger dru

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.